Search - tctmd.com

Displaying 161 - 180 of 325

Sort: Relevancy | Date

Presentation TCT 2018

In 2018 When Is Warfarin Therapy Required vs Acceptable, and How Should it Be Dosed After PCI?

Presenter: Davide Capodanno, Giulio Stefanini, Freek W.A. Verheugt

September 23, 2018

Presentation TCT 2018

Has PIONEER and REDUAL Changed My Practice? What Are the Outstanding Issues?

Presenter: Davide Capodanno, Giulio Stefanini, C. Michael Gibson

September 23, 2018

Presentation TCT 2018

Pharmacotherapy Challenges and Possible Solutions in the PCI Patient on Chronic Oral Anticoagulation

Presenter: Davide Capodanno, Giulio Stefanini, Tullio Palmerini

September 23, 2018

Presentation TCT 2018

Utility of Cangrelor During PCI and Bridging Who Benefits Most?

Presenter: John A. Bittl, C. Michael Gibson, Deepak L. Bhatt

September 23, 2018

Presentation TCT 2018

How Strong are the Pharmacodynamic Data and Clinical Evidence for Crushed Ticagrelor and Prasugrel?

Presenter: John A. Bittl, C. Michael Gibson, Dimitrios Alexopoulos

September 23, 2018

Presentation TCT 2018

The Case for Bivalirudin With Radial (and Femoral) Access

Presenter: John A. Bittl, C. Michael Gibson, Carey D. Kimmelstiel

September 23, 2018

Presentation TCT 2018

The Latest Antithrombotic Data: MATRIX at 1 Year

Presenter: John A. Bittl, C. Michael Gibson, Stephan Windecker

September 23, 2018

Presentation TCT 2018

Switching Dual Antiplatelet Therapy After PCI: Who, When, Why, and How?

Presenter: John A. Bittl, C. Michael Gibson, Matthew J. Price

September 23, 2018

News Daily News TCT 2018

High Mortality but Durable Results With Valve-in-Valve TAVR

Michael O'Riordan

September 23, 2018

Presentation TCT 2018

Benefits of Pretreatment With Dual Antiplatelet Therapy Prior to PCI in Stable CAD and ACS: Myth or Reality?

Presenter: John A. Bittl, C. Michael Gibson, Giuseppe Tarantini

September 23, 2018

Presentation TCT 2018

Featured Lecture: Does the Polypill Enhance Drug Adherence and Improve Cardiovascular Outcomes?

Presenter: John A. Bittl, C. Michael Gibson, Valentin Fuster

September 23, 2018

Presentation TCT 2018

EWOLUTION: Two-Year Efficacy of Left Atrial Appendage Closure in High-Risk Patients - Single Antiplatelet/No Therapy Subgroup Analysis

Presenter: Horst Sievert, Brian K. Whisenant, Martin W. Bergmann

September 23, 2018

Polymer-Free BioFreedom Stent as Safe as Orsiro, but Not as Effective

News Conference News TCT 2018

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

Michael O'Riordan

September 22, 2018

News Conference News TCT 2018

ReCre8: Physician-Led Study Shows Noninferiority of Polymer-Free Stent Compared With Permanent-Polymer ZES at 1 Year

Yael L. Maxwell

September 22, 2018

Presentation TCT 2018

LEADERS FREE II: Evaluation of a Polymer-Free Coronary Drug-Eluting Stent in High Bleeding-Risk Patients With One-Month Dual Antiplatelet Therapy

Presenter: Mitchell W. Krucoff

September 22, 2018

News Conference News TCT 2018

The End of BMS? LEADERS FREE II Shows Superiority of Polymer-Free, Drug-Coated Stent

Yael L. Maxwell

September 22, 2018

News Opinion Editor's Corner TCT 2018

TCT 2018, Day One: ‘Back to the Future’ With Stents, Stents, and More Stents

Shelley Wood

September 22, 2018

News Conference News TCT 2018

Novel LAA Closure Device Shows Promise in Early Experience

L.A. McKeown

September 22, 2018

Presentation TCT 2018

TCT-1: Optimal Duration of Dual Antiplatelet Therapy After Left Main Coronary Stenting With Everolimus-Eluting Stents: Analysis From the EXCEL Trial

Presenter: Steven R. Bailey, Patrick W. Serruys, Sorin J. Brener

September 22, 2018

News Conference News TCT 2018

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

Shelley Wood

September 17, 2018

Advertisement

In 2018 When Is Warfarin Therapy Required vs Acceptable, and How Should it Be Dosed After PCI?

Has PIONEER and REDUAL Changed My Practice? What Are the Outstanding Issues?

Pharmacotherapy Challenges and Possible Solutions in the PCI Patient on Chronic Oral Anticoagulation

Utility of Cangrelor During PCI and Bridging Who Benefits Most?

How Strong are the Pharmacodynamic Data and Clinical Evidence for Crushed Ticagrelor and Prasugrel?

The Case for Bivalirudin With Radial (and Femoral) Access

The Latest Antithrombotic Data: MATRIX at 1 Year

Switching Dual Antiplatelet Therapy After PCI: Who, When, Why, and How?

High Mortality but Durable Results With Valve-in-Valve TAVR

Benefits of Pretreatment With Dual Antiplatelet Therapy Prior to PCI in Stable CAD and ACS: Myth or Reality?

Featured Lecture: Does the Polypill Enhance Drug Adherence and Improve Cardiovascular Outcomes?

EWOLUTION: Two-Year Efficacy of Left Atrial Appendage Closure in High-Risk Patients - Single Antiplatelet/No Therapy Subgroup Analysis

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

ReCre8: Physician-Led Study Shows Noninferiority of Polymer-Free Stent Compared With Permanent-Polymer ZES at 1 Year

LEADERS FREE II: Evaluation of a Polymer-Free Coronary Drug-Eluting Stent in High Bleeding-Risk Patients With One-Month Dual Antiplatelet Therapy

The End of BMS? LEADERS FREE II Shows Superiority of Polymer-Free, Drug-Coated Stent

TCT 2018, Day One: ‘Back to the Future’ With Stents, Stents, and More Stents

Novel LAA Closure Device Shows Promise in Early Experience

TCT-1: Optimal Duration of Dual Antiplatelet Therapy After Left Main Coronary Stenting With Everolimus-Eluting Stents: Analysis From the EXCEL Trial

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content